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Heparan sulfate (HS) and its highly modified form, 3-O-sul-
fated heparan sulfate (3-OS HS), contribute strongly to herpes
simplex virus type-1 (HSV-1) infection in vitro. Here we report
results from a random M13-phage display library screening to
isolate 12-mer peptides that bind specifically to HS, 3-OS HS,
and block HSV-1 entry. The screening identified representative
candidates from two-different groups of anti-HS peptides with
high positive charge densities. Group 1, represented by G1 pep-
tide (LRSRTKIIRIRH), belongs to a class with alternating
charges (XRXRXKXXRXRX), and group 2, represented by G2
peptide (MPRRRRIRRRQK), shows repetitive charges (XXR-
RRRXRRRXK). Viral entry and glycoprotein D binding assays
together with fluorescent microscopy data indicated that both
G1 and G2 were potent in blocking HSV-1 entry into primary
cultures of human corneal fibroblasts and CHO-K1 cells tran-
siently expressing different glycoprotein D receptors. Interest-
ingly, G2 peptide isolated against 3-OSHS displayed wider abil-
ity to inhibit entry of clinically relevant strains of HSV-1 and
some divergent members of herpesvirus family including cyto-
megalovirus and human herpesvirus-8. To identify functional
residues within G1 and G2, we performed point mutations and
alanine-scanningmutagenesis. Several arginine and a lysine res-
idues were needed for anti-HSV-1 activity, suggesting the
importance of the positively charged residues in virus-cell bind-
ing and virus-inducedmembrane fusion. In vivo administration
of G1 or G2 peptide as a prophylactic eye drop completely
blockedHSV-1 spread in themouse cornea as evident by immu-
nohistochemistry. This result also highlights an in vivo signifi-
cance of HS and 3-OS HS during ocular herpes infection.
Heparan sulfate (HS)2 moieties present on cell surfaces pro-
vide attachment sites for many human and non-human patho-
genic viruses including herpes simplex virus type-1 and -2
(HSV-1 and HSV-2) (1–4). Both wild-type and laboratory
strains of HSV (5) bind HS. In addition to the attachment step,
HSV-1 penetration into cells can also be mediated by 3-O-sul-
fated heparan sulfate (3-OS HS), which is produced after a rare
enzymatic modification in HS catalyzed by 3-O-sulfortrans-
ferases (3-OSTs) (6–11). HSV envelope glycoproteins B and C
bindHS andmediate virus attachment to cells (2, 3, 12). A third
glycoprotein, gD, specifically recognizes 3-OS HS, and this
interaction can facilitate fusion pore formation during viral
entry (6, 7, 13). Despite the known importance of HS and 3-OS
HS during HSV-1 infection in vitro (14, 15), not much is known
about their significance during an actual infection in vivo.
The versatile ability of HS to bind a slue of microbes and
participate in a variety of regulatory phenomena comes from its
negatively charged nature and highly complex structure gener-
ated by enzymatic modifications (4, 16). Virtually all cells
express HS as long un-branched chains often associated with
protein cores commonly exemplified by syndecan and glypican
families of HS proteoglycans (16). The parent HS chain, which
contains repeating glucosamine andhexuronic acid dimers, can
be 100–150 residues long and may contain multiple structural
modifications. Most common among them is the addition of
sulfate groups at various positionswithin the chain, which leads
to the generation of specificmotifs,makingHShighly attractive
formicrobial adherence (4, 14, 15). Emerging evidence suggests
that the role of HS in viral infection goes well beyond a role as a
low specificity pre-attachment site. For instance, HS mediates
HSV-1 transport on filopodia during surfing (17) andnegatively
regulates virus-induced membrane fusion (14). Likewise, for
human papilloma virus, HS proteoglycans play a key role in the
activation of immune response, an important aspect for both
vaccine development and human papilloma virus pathogenesis
(18). Similarly, HS expressed on spermatozoa plays a key role in
the capture of human immunodeficiency virus (HIV) and its
transmission to dendritic, macrophage, and T cells (19). 3-OS
HS also plays a role in hepatitis B virus replication (20) and
HS-binding peptides, or compounds can be successfully used
for preventing genital human papilloma virus, HIV, and cyto-
megalovirus infection (21–24).
Despite the promise HS may show in anti-HSV therapy, vir-
tually no products exist that target HS against human infec-
tions. Random peptide library screening has been used in the
past to identify small peptides that specifically bind to unique
immobilized protein targets and receptors expressed on cul-
* This work was supported, in whole or in part, by National Institutes of Health
Grants RO1 AI057860 (to D. S.) and AI050050 (to J. L.) and Core Grant
EY001792 (to the University of Illinois at Chicago). Part of this work was
made possible by an award from the Glaucoma Foundation (to D. S.).
1 To whom correspondence should be addressed: 1855 W. Taylor St. (M/C
648), Chicago, IL 60612. Tel.: 312-355-0908; Fax: 312-996-7773; E-mail:
dshukla@uic.edu.
2 The abbreviations used are: HS, heparan sulfate; 3-OS HS, 3-O-sulfated
heparan sulfate; gD, glycoprotein D; CF, corneal fibroblasts; HHV-8,
human herpesvirus-8; RPE, retinal pigment epithelial; HCjE, human con-
junctival epithelial; pfu, plaque forming unit; ONPG, o-nitrophenyl--D-
galactopyranoside; X-gal, 5-bromo-4-chloro-3-indolyl--D-galactopy-
ranoside; Cp, control peptide; 3-OST, 3-O-sulfortransferase; 3-OST-3,
3-O-sulfotransferase-3.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 286, NO. 28, pp. 25406 –25415, July 15, 2011
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
25406 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 28 • JULY 15, 2011
tured cells (25). The present study identifies and characterizes
an anti-HS peptide, G1, and an anti-3-OS HS peptide, G2, that
significantly inhibit HSV-1 infection and receptor-mediated
cell-to-cell fusion in vitro. G2 peptide shows the extra promise
of blocking infection of a divergent group of herpesviruses. The
peptides also inhibit HSV-1 spread in amousemodel of corneal
keratitis. To our knowledge, G1 and G2 peptides represent two
novel classes of relatively small cationic peptides specifically
isolated against HS and 3-OSHS, respectively, with strong her-
pesvirus entry-inhibiting activities. Inhibition of HSV-1 infec-
tion in themouse cornea is the first demonstration of an in vivo
significance of HS/3-OS HS in HSV-1 pathogenesis.
EXPERIMENTAL PROCEDURES
Selection of Phages against HS and 3-OS HS by Library
Panning—A phage display library (PhDTM-12) expressing
12-mer peptides fused to a minor coat protein (pIII) of a non-
lytic bacteriophage (M13) was purchased from New England
Biolabs (Cambridge, MA). A purified form of HS isolated from
bovine kidney was purchased from Sigma. Soluble 3-OS HS
modified by 3-OST-3 was prepared as previously described
(26). Screening of the phage display library was accomplished
by an affinity selection (or bio-panning) process during which
phage populations were selected for their ability to bindHS and
3-OS HS (modified by 3-OST-3). Both targets at a concentra-
tion of 10 g/ml were used for overnight coating of wells of
96-well plates (Nalge Nunc International, Naperville, IL) in a
humidifier chamber at 4 °C. The following day, the plates were
blocked for 1 h at room temperature with 5 mg/ml bovine
serum albumin in 0.1 M NaHCO3, pH 8.6, buffer. The plates
were then washed 6 times with TBST (50mMTris-HCl, pH 7.5,
150 mM NaCl, 0.1% (v/v) Tween 20). The phage library was
added to the plate at a concentration of 2  1011 in 100 l in
TBST.The platewas gently rocked for 1 h at room temperature.
Unbound phages were removed by washing plates 10 times
with 1 ml of TBST. Bound phages were eluted by adding 100 l
of Tris-HCl at pH 3.0. The eluate containing bound phages was
removed, and the phages were amplified in Escherichia coli
ER2738 bacteria and partially purified by polyethylene glycol
precipitation. The binding, elution, and amplification steps
were repeated using HS and 3-OST-3 modified HS as targets.
Three rounds of selection were carried out to select for the
specific binders. Low concentrations of detergent (Tween 20)
in the early rounds resulted in high eluate titers, and the strin-
gency was gradually increased with each round by raising
Tween 20 concentration stepwise to a maximum of 0.5%. This
allowed selection of high affinity binding phages. For final selec-
tion, the eluted phageswere plaque-purified and tittered on soft
agar plates.
Nucleotide Sequencing andAnalysis—Automated nucleotide
sequencing was performed to determine the sequences of the
peptides encoded by the phages (Research Resource Center,
University of Illinois at Chicago). The phage DNAwas purified
according to the manufacture’s protocol using Qiagen mini-
prep kit (Valencia, CA). DNA sequencing was initiated using
ABI prism BigDye Terminator kit (Applied Biosystems, Foster
City, CA) and the 96 gIII sequencing primer (New England
Biolabs). Sequencing was performed on a Hitachi 3100 gene
analyzer (Applied Biosystems), and the 36-nucleotide-long
DNA region encoding the 12-mer peptides was identified and
used for peptide synthesis. The synthetic peptides were resus-
pended at a concentration of 10 mM in phosphate buffer saline
(PBS) at pH 7.4 and stored at 80 °C until use. The University
of Illinois Research Resource Center was used for generating all
the peptides and a few mutant peptides. The peptides for Ala-
scanning mutagenesis were synthesized by GenScript Inc. The
purity of the peptides was 95% as verified by high perform-
ance liquid chromatography, and the correct mass was con-
firmed by mass spectrometry.
Cell Culture and Viruses—Various cell types used in this
study included wild-type Chinese hamster ovarian (CHO-K1),
mutantCHO-745, andCHO-I8 cells. In addition, primary cul-
tures of human corneal fibroblasts (CFs), retinal pigment epi-
thelial (RPE), human conjunctival epithelial (HCjE), Vero and
HeLa cells were also used. CHO-K1cells were provided by P. G.
Spear (Northwestern University, Chicago). HeLa cells were
provided by B.P. Prabhakar (University of Illinois at Chicago).
All CHO cell lines were grown in Ham’s F-12medium (Invitro-
gen) supplementedwith 10% fetal bovine serum (FBS) and pen-
icillin and streptomycin (Invitrogen). CF, HeLa, and RPE cells
were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 10% FBS and penicillin and streptomycin (27, 28),
and Vero cells were grown in DMEMwith 5% FBS and penicil-
lin and streptomycin. Cultured HCjE cells provided by Dr. Illne
Gipson (HarvardMedical School) were grown as described pre-
viously (29). The -galactosidase expressing recombinant
HSV-1(KOS)gL86 virus strain was provided by P. G. Spear.
Similarly, HSV-1 strains used in this study (17, HfM, F,MP, and
KOS) and HSV-2 G were also kindly provided by Dr. Spear.
Green fluorescent protein (GFP) expressing HSV-1(K26GFP)
and GFP expressing human herpesvirus-8 (HHV-8) were gen-
erous gifts, respectively, provided byDrs. PrashantDesai (Johns
Hopkins University) (30) and J. Viera (University of Washing-
ton). The -galactosidase-expressing recombinant cytomega-
lovirus (CMV) was obtained from ATCC.
HSV-1 Entry Assay—A previously described HSV-1 entry
assay was used (6). CHO-K1 cells were grown in 6-well plates to
subconfluence and then transfected with 2.5 g of expression
plasmids for gD receptors nectin-1 (pBG38), Herpesvirus Entry
Mediator (pBec10), 3-OST-3 isoform (pDS43), or pCDNA3.1
(empty vector) using Lipofectamine (Invitrogen). At 16 h post-
transfection, the cells were replated into 96-well dishes for pre-
incubation with peptides at different concentrations for 60min
at room temperature. In parallel, natural target cells (HeLa, CF,
and RPE) were also pretreated with the peptides for the same
duration. In all cases the unbound peptides were removed after
washing 3with PBS. Thereafter, the cells were infected for 6 h
with a recombinant virus, HSV-1(KOS)gL86, at multiple
plaque-forming units (pfu), and -galactosidase assays were
performed using either a soluble substrate o-nitrophenyl--D-
galactopyranoside (ONPG at 3.0 mg/ml; ImmunoPure, Pierce)
or X-gal (Sigma). For the soluble substrate, the enzymatic activ-
ity was measured at 410 nm using a microplate reader (Spectra
Max 190, Molecular Devices, Sunnyvale, CA). For the X-gal
assay, cells were fixed (2% formaldehyde and 0.2% glutaralde-
hyde) and permeabilized (2 mM MgCl2, 0.01% deoxycholate,
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and 0.02% nonidet Nonidet P-40 (Sigma)). Finally, 1ml of-ga-
lactosidase reagent (1.0mg/ml X-gal in ferricyanide buffer) was
added to each well and incubated at 37 °C for 90 min before the
cells were examined using bright field microscopy under the 20
objectives of the invertedmicroscope (Zeiss Axiovert 100M).
FluorescentMicroscopy of Viral Entry—Culturedmonolayers
of HeLa and CF cells (106 cells/well) were grown overnight in
DMEM media containing 10% FBS on chamber slides (Lab-
Tek). One pool of each cell type was pretreated with G1, G2, or
a control peptide for 60 min. The cells were then infected with
HSV-1(K26GFP) (30) at 50 pfu in serum-freemediaOpti-MEM
(Invitrogen), and this was followed by fixation of cells at 90min
post-infection using fixative buffer (2% formaldehyde and 0.2%
glutaraldehyde). The cells were thenwashed and permeabilized
with 2mMMgCl2, 0.01% deoxycholate and 0.02%Nonidet P-40
for 20min. After rinsing, 10 nM rhodamine-conjugated phalloi-
din (Invitrogen)was added for F-actin staining at room temper-
ature for 45min. Finally, the cells were washed, and the images
of labeled cells were acquired using a confocal microscope (Leica,
Solms, Germany) and analyzed withMetaMorph software.
CMV Entry Assay—Natural target RPE cells were incubated
with G1 and G2 peptides for 60 min at room temperature
before the cells were infected with -galactosidase expressing
CMV (ATCC) for 8 h. -Galactosidase assays were performed
using either a soluble substrate o-nitrophenyl--D-galactopyra-
noside (ONPG at 3.0 mg/ml; ImmunoPure, Pierce) or X-gal
(Sigma).
HHV-8 Infection Assay—HCjE cells grown in chamber slides
(Labteck) or in a 96-well plate were pretreated with G1, G2, or
control peptides for 60 min at room temperature followed by
inoculation with recombinant rHHV-8.152, expressing the
GFP (31). 48 h post-infectionGFP-positive cells were visualized
undermicroscope (ZeissAxiovert 100M).HHV-8 infectionwas
determined as relative fluorescence units using a GENios Pro
plate reader (TECAN) at 480-nm excitation and 520-nm emis-
sion frequencies. Five measurements of negative control, posi-
tive control, and the test samples were performed. Data are
expressed as the mean  S.D.
HSV-1 Glycoprotein Induced Cell-to-cell Fusion Assay—In
this experiment the CHO-K1 cells (grown in F-12Ham’s, Invit-
rogen), designated “effector” cells, were co-transfected with
plasmids expressing four HSV-1(KOS) glycoproteins, pPEP98
(glycoprotein B), pPEP99 (glycoproteinD), pPEP100 (glycopro-
tein H), and pPEP101 (glycoprotein L) along with the plasmid
pT7EMCLuc that expresses firefly luciferase gene under the T7
promoter (32).Wild-typeCHO-K1 cells express cell surfaceHS
but lack functional gD receptors and, therefore, are transiently
transfected with HSV-1 entry receptors. Wild-type CHO-K1
cultured cells expressing HSV-1 entry receptors or naturally
susceptible cells (human CFs) considered as “target cells” were
co-transfected with pCAGT7 that expresses T7 RNA polymer-
ase using chicken actin promoter and CMV enhancer (33). The
untreated effector cells expressing pT7EMCLuc and HSV-1
essential glycoproteins and the target cells expressing gD recep-
tors transfected with T7 RNA polymerase were used as the
positive control. G2 or control peptide-treated target cells were
then co-cultivated (1:1 ratio) for 18 h with effector cells for
fusion. Activation of reporter luciferase gene as a measure of
cell fusionwas examined using reporter lysis assay (Promega) at
24 h post-mixing.
Flow Cytometry Analysis—Flow cytometry was performed to
detect the effect of G2 peptide on GFP-HSV-1 binding to
human CFs. Monolayers of 5  106 CFs were pretreated with
G2 peptide for 60 min followed by incubation with GFP-ex-
pressing HSV-1(K26GFP) at 4 °C. Control peptide-treated or
-untreated cells were similarly incubated with HSV-1 GFP viri-
ons. UninfectedCFswere used as the backgroundnegative con-
trol. GFP expression from the viral capsid on cell surface was
examined by a flowcytometer (MoFlo).
Immunohistochemistry—BALB/cmice with pre-scarred cor-
neal upper surface were treated with PBS-based eye drops con-
taining 0.5 mMG1, G2, or control peptide followed by the inoc-
ulation of HSV-1(KOS). The mice were sacrificed after 4 and 7
days for HSV-1 detection. Immunohistochemistry was per-
formed as described previously (29). Briefly, the tissue sections
were hydrated with distilled water, and antigen retrieval was
performedusingDAKOTarget Retrieval Solution 10 concen-
trate (DAKO, Carpinteria, CA). Nonspecific staining was
blocked using an H2O2 solution for 10 min followed by a pro-
tein block for 10 min. Sections were incubated with HSV-1
gD-specific antiserum (1:100 dilution) at room temperature for
1 h followed by a 40-min incubation with the secondary anti-
body (HRP-conjugated goat anti-rabbit IgG, 1:500; Sigma).
Expression of gD was detected using the DAKO Envision kit.
Confocal and differential interference contrast image acquisition
was conducted with an SB2-AOBS confocal microscope (Leica).
Statistics—The data presented are the means  S.D. of trip-
licate measures of three or more experiments performed inde-
pendently. Error bars represent the S.D. Statistical significance
was calculated using Student’s t test. A p value that was 0.05
was considered statistically significant.
RESULTS
Identification of HS and 3-OS HS-binding Peptides That
Block HSV-1 Entry—Three rounds of screening of phages from
a 12-mer peptide phage display library resulted in the enrich-
ment of phages that bound HS or 3-OS HS. Peptide sequences
from individual plaques were deduced by determining the
nucleotide sequences of the portion of the phage genome that
encoded them. The predicted peptide sequences of about 200
plaques were determined and sorted into two groups on the
basis of their targets. A frequently repeating peptide sequence
from each group was subsequently selected for further charac-
terization. The twomost frequently isolated peptide sequences
LRSRTKIIRIRH (called G1 for HS binding group 1) and
MPRRRRIRRRQK (G2 for 3-OSHS binding group 2) were syn-
thesized and examined for their abilities to inhibitHSV-1 entry.
Both peptides were able to block HSV-1 entry into CHO-K1
cells expressing one of the three gD receptors, 3-OS HS, nec-
tin-1, andHVEM. The blockage of entry occurred in a dose-de-
pendent manner (Fig. 1) and it was independent of the gD
receptor used. The concentration of each peptide that produces
50% of its maximum potential inhibitory effect (IC50) was
determined. IC50 values ranged from0.02 to 0.03mM.A control
phage bearing the sequence RVCGSIGKEVLG (designated
control peptide (Cp)) did not inhibit HSV-1 entry, and none of
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the peptides showed any significant cytotoxicity (MTS assay
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium), Promega) at 5 mM or below
concentrations. The highest concentration of the peptides in
our experiments was kept at 0.5 mM.
We next compared the abilities of the G1 and G2 peptides to
block HSV-1 entry into natural target cells (HeLa and primary
cultures of human CF). Again, a similar dosage response curve
was generated when HeLa (Fig. 2A) or CF (Fig. 2B) cells were
pretreated with G1 or G2 peptides during HSV-1 entry. The
control peptide-treated cells had no effect onHSV-1 entry (Fig.
2). Use of insoluble blue cell assay (X-gal as the substrate for
-galactosidase) further confirmed that the peptides were
effective in blocking infection of individual cells (Fig. 2,A andB,
right panels). In virtually all cases, G2 peptide was slightly more
effective in blocking entry than G1.
The Peptide Inhibitors Are Also Active against a Variety of
HSV-1 Strains—Next we evaluated the anti-HSV properties of
G1 andG2peptides against other commonly used strains (F and
G, Hfem,MP, KOS, and 17) of HSV-1 andHSV-2 (34). Here we
FIGURE 1. Inhibition of HSV-1 entry by 12-mer synthetic peptides is not
specific to any particular gD receptor. G1 and G2 peptides were examined
for their ability to block HSV-1 infection of 3-OST-3 (panel A)-, nectin-1 (panel
B)-, and Herpesvirus Entry Mediator (panel C)-expressing CHO-K1 cells. Cells
were preincubated with G1, G2, or control peptide (abbreviated as Cp) at the
indicated concentrations in mM or mock-treated (abbreviated as C) with 1
phosphate saline buffer for 60 min at room temperature. After 60 min, a -ga-
lactosidase-expressing recombinant virus HSV-1(KOS)gL86 (25 pfu/cell) virus
was used for infection. After 6 h, the cells were washed, permeabilized, and
incubated with ONPG substrate (3.0 mg/ml) for quantitation of -galactosid-
ase activity expressed from the input viral genome. The enzymatic activity
was measured at an optical density of 410 nm. Each value shown is the mean
of three or more determinations (S.D.).
FIGURE 2. G1 and G2 peptides block HSV-1 entry into human target cells.
HeLa cells (panel A) and primary cultures of human CFs (panel B) were tested.
Cells in 96-well plates were pretreated for 60 min with indicated mM concen-
trations of G1, G2, or Cp peptides. Mock-treated cells (abbreviated as C)
served as a control. Pretreated cells were infected with a  galactosidase-
expressing recombinant virus HSV-1(KOS)gL86 (25 pfu/cell) for 6 h. Viral entry
was quantitated as described in Fig. 1. Confirmation of HSV-1 entry blocking
activity of G1, G2, and Cp peptides on a per cell basis was obtained after cells
were infected as described above followed by X-gal (1.0 mg/ml) staining
(right panels), which yields an insoluble blue product upon hydrolysis by
-galactosidase expressed from the input viral genomes. Dark stained cells
represent infected cell; uninfected cells stay transparent. Microscopy was per-
formed using a 20  objective of Zeiss Axiovert 100.
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used 3-OST-3-expressing CHO Ig8 reporter cells that express
-galactosidase upon viral entry (35). The cells were preincu-
bated with G1, G2, or Cp and subsequently infected with the
viruses. The results from this experiment again showed that G2
(and similarly, G1; data not shown) blocked entry of various
HSV-1 strains by 70–80% at 0.5 mM concentration (Fig. 3).
Clearly, the inhibitory effect of G2 peptide was broad and not
limited to any particular strains or serotypes.
Structural Aspects of G1 and G2 Peptides: G2 Shows More
Dependence on Charged Residues—To better understand the
inhibitory potential of G1 andG2 peptides, we decided tomake
synthetic short versions (10-mer) lacking the terminal non-
positively charged amino acids. In the case of G1, N-terminal
Leu and C-terminal His residues were removed, and for G2, the
N-terminal flanking residues (Met and Pro) were removed.We
worked on a hypothesis that 12-mer peptides are too short to
have any secondary or tertiary structure; therefore, their pri-
mary structure and most likely the presence of positively
charged residues alone play a critical role during HSV-1 entry
inhibition. As shown in Fig. 4A, the 10-mer version of G2 was
very similar to the 12-mer in its ability to block HSV-1 entry
into CFs. In contrast, the 10-mer version of G1 peptide almost
completely lost its ability to block HSV-1 entry into the target
cells. Thus, it is likely that terminal Leu andHis are required for
the anti-HSV-1 activity of G1. G2, on the other hand, relies
more on its charged residues for its functional activity. To prove
this point, we decided to perform alanine-scanning mutagene-
sis. It is commonly used to identify specific amino acid residues
responsible for peptide function, stability, and conformation
(36). Synthetic peptides weremade whereby each residue of G2
was sequentially replaced with an Ala residue, and correspond-
ing changes inG2peptidewere evaluated for the ability to affect
viral entry (Fig. 4B). Quite interestingly, we found that the first
four Arg residues were essential, whereas the middle two could
be substituted with moderate loss of activity. The last Arg and
Lys were also essential. Interestingly, the uncharged residues
tolerated the substitutions well. Under similar experimental
conditions, G2 oligomers were also examined, and it was evi-
dent that they blocked infection about 2-fold better than G1
(Fig. 4B). To conclude, ourmutagenesis results suggest that the
presence of positively charged residues plays an important role
in HSV-1 entry blocking activity shown by G2.
G2 Represents a Class of Broad Spectrum Anti-HS Peptides
withActivity againstMultipleHerpesviruses—Usage of cell sur-
face HS moieties during viral binding and entry is a unique
feature that is shared by many infectious viruses including
many herpesviruses (7). It is well documented that similar to
HSV-1 (an -herpesvirus), - herpesvirus (CMV) and HHV-8
also use HS during cell entry and fusion (4, 7). Therefore, we
made an optimistic attempt to test if G1 and G2 can also block
infection of othermembers of herpesvirus family. To detect the
peptide effect on viral entry, we used LacZ-expressing reporter
FIGURE 3. HSV-1 entry blocking activity of G2 peptide is not HSV-1 strain-
specific. G2 (gray or white bars) or Cp control (black bars) at 0.5 mM concen-
tration was incubated for 60 min at room temperature with reporter CHO-Ig8
cells that express -galactosidase upon HSV-1 entry. After incubation, the
cells were infected with HSV-1 (Pal, 17, Hfm, glycoprotein F, KOS, and MP) and
HSV-2 (G) strains indicated above at 25 pfu/cell for 6 h at 37 °C. The viral entry
blocking was measured by ONPG assay as described in Fig. 1.
FIGURE 4. Deletion analysis and alanine-scanning mutagenesis reveal
significance of positively charged residues in HSV-1 entry inhibition.
A, synthetic 10-mer versions of G1 and G2 (shown above) were tested for
blocking HSV-1(KOS)gL86 entry into cultured CF. After 6 h, the viral entry was
measured by ONPG assay as described in Fig. 1. B, alanine-scanning mutagen-
esis was performed on G2. Twelve different peptides were synthesized
replacing one residue at a time with an Ala, and their entry blocking activity
was determined as described above. The location of Ala in the peptide is
denoted by a number next to it, Cp represents the control peptide, and the
oligomeric G2 is listed as G2 oligomers (G2-O). The figure shows relative loss
of inhibitory potential upon substitution of a residue within G2 by an Ala.
Activity of each peptide was normalized against the wild-type G2, which was
kept at 1.00. Numbers higher than 1 show loss of activity, whereas a lower
number represents gain of activity.
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CMV and GFP-expressing HHV-8 viruses (31) and employed
their natural target cells for entry measurements. Surprisingly,
G2 but not G1 peptide showed clear effects against CMV and
HHV-8 (Fig. 5). As shown in Fig. 5A, G2 peptidewas effective in
blocking CMV entry into RPE cells, whereas G1 peptide had no
effect. In essence, the effect of G1 was similar to the Cp or
peptide-untreated cells, and the same pattern was repeated
when the effects of the peptides were examined on a per cell
basis by an X-gal assay (Fig. 5B). In parallel, the ability to block
HHV-8 infection was examined in HCjE cells, a natural target
for HHV-8 infection. Emission of fluorescence indicates virus
infection. As shown in Fig. 5C, compared with G1- or
Cp-treated cells G2-treated HcjE cells had relatively very low
GFP expression. This suggests that G2 was able to block infec-
tion, and the result is statistically significant. Although G1 also
demonstrated some lowering of fluorescence in the represen-
tative case shown in Fig. 5C, we did not find it statistically
significant upon repeated experiments. This fact was also
confirmed when individual cells were examined under a fluo-
rescence microscope. Cells treated with G2 did not show fluo-
rescence originating fromGFP virus replication (Fig. 5D). How-
ever, the fluorescence was more easily seen with G1- or
Cp-treated cells. The results suggest that G2 is more effective
that G1 in blocking entry of divergent herpesviruses. G1 may
have some activity, but the virus can possibly overcome it easily.
Mechanism for HSV-1 Entry Inhibition by the Peptides—Be-
cause G2 peptide showed significant blocking activity against
multiple herpesviruses, we focused our attention on G2 to
determine how it may function to block infection. One possible
explanation is based on its ability to block the sites on HS that
FIGURE 5. G2 also blocks entry of representative members of - and -herpesvirus subfamilies (CMV and HHV-8). A, a monolayer of cultured RPE cells
grown in a 96-well plate was pretreated with G1, G2, or Cp at 0.5 mM concentration. A mock-treated population of RPE cells served as the positive control
(abbreviated as C). After 60 min of incubation at room temperature, the cells were infected with -galactosidase expressing CMV reporter virus. After 8 h, viral
entry was measured as described for Fig. 1. B, effect of CMV entry blocking activity of G1, G2, or Cp peptide for individual RPE cells was determined by X-gal
staining, which yields an insoluble blue product upon hydrolysis by -galactosidase. Individual cells were examined using Zeiss Axiovert 100 microscope at
20 magnification. Infected cells turn blue. C, HCjE cells preincubated with G1, G2, or Cp were infected with HHV-8 virions for 48 h at 37 °C. After incubation, the
cells were washed thoroughly to remove unbound viruses. GFP-expression of HHV-8 was quantitated by determining relative fluorescence units using a
96-well fluorescence reader (TECAN). The data shown are the means of triplicate measures and are representative of three independent experiments. D, viral
replication in HCjE cells were visualized under fluorescent microscope (Zeiss Axiovert 100) in cells that were pretreated with G1, G2, or Cp as described above.
Asterisks indicate significant difference from controls and/or treatments (p  0.05, t test), and error bars represent S.D.
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may otherwise bind the virus. To examine this, we made use of
a GFP-tagged HSV-1(K26GFP) virus. Cultured CF were prein-
cubated with 0.5 mM G2 peptide or Cp and then infected with
the GFP virus. Cells were fixed at 60 min post-infection and
stained for F-actin (red) and the nucleus (DAPI, blue). It was
evident that G2-treated cells resisted virus attachment (Fig. 6A,
green) compared with the control peptide-treated cells. To
examine this effect on a population of 105 cells, GFP intensity as
an indicator of virus binding was measured after incubation
with the virus in cold and rigorous washing of the cells after-
ward (Fig. 6B). Clearly, the binding was significantly higher in
Cp-treated compared with G2 peptide-treated cells. These
results together with those of the entry assay and visualization
of GFP-tagged HSV-1 suggest that pretreatment of cells with
G2 peptide significantly blocks virus attachment and, hence,
the entry of HSV-1 into natural target cells.
G2 Peptide Acts by Inhibiting HSV-1 Binding to HS—Next,
we evaluated the effect of G2 on virus binding by flow cytom-
etry. We reasoned that a GFP reporter virus binding on cells
pretreatedwithG2will be significantly reduced, and this should
be detectable by flow cytometry. Primary cultures of humanCF
pretreated with G2 peptide or control peptide (C) were ana-
lyzed for HSV-1(K26GFP) binding. The peptide-untreated CF
incubated with the virus served as a positive control, whereas
the uninfected peptide was kept as a negative background con-
trol. Our results indicate that the virus failed to bind G2 pep-
tide-treated CF (Fig. 6C). For unknown reasons, the control
peptide also showed some inhibition of binding, but the effect
ofG2was farmore evident. This result confirms thatG2 has the
ability to block virus attachment to cells. To further confirm
that blocking of the attachment means no virus replication
either, we monitored fluorescence over time as a measure of
K26GFP (30) virus production in G2-treated andmock-treated
cells. The GFP intensity (representing virus production)
increased significantly over time (Fig. 6D) inmock-treated cells
but not when the cells were treated with G2. Thus, our result
suggests that G2 can block virus binding to a level that no rep-
lication can be detected.
FIGURE 6. G2 functions by preventing HSV-1 attachment to cells, which results in loss of binding and viral replication. A, GFP-expressing HSV-1(K26GFP)
binding to CF in the presence and absence of G2 peptides was examined by fluorescence microscopy. CF were grown in collagen-coated chamber slides and
incubated at room temperature for 60 min with G2 () or control Cp (G2 ()) peptide. This was followed by the incubation of the cells in cold with GFP-
expressing HSV-1(K26GFP) for 30 min and washing of unbound virioins with PBS. Cells were fixed, stained with phalloidin for F-actin (red) and DAPI for nuclei
(blue), and examined by a fluorescence microscope (Leica, SP2). The presence of the virus is shown in green. B, relative virus binding to CF was estimated by
fluorescence measurements. Cultured CF were preincubated with G2 and Cp for 60 min before ice-cold incubation with GFP-expressing HSV-1 virus for 30 min.
Cells were washed 3 times, and viruses remaining on cell surfaces were assayed for GFP fluorescent intensity using a fluorescence reader (Tecan). C, GFP-
expressing HSV-1(K26GFP) intensity as a surrogate for virus binding was quantified in presence G2 or control peptide (abbreviated as C) by flow cytometry. The
cell/virus incubation was performed as described above. D, G2 peptides block HSV-1 replication into cultured human CFs. Cultured CF were preincubated with
G2 or mock-treated (Cp) before infection with HSV-1(K26GFP) virus for 6 h. Viral replications in CF were quantified 0 –36 h post-infection by measuring GFP
fluorescent intensity using a fluorescence reader (Tecan). The data shown are the means of triplicate measures and are representative of three independent
experiments. Asterisks indicate significant difference from other treatments (p  0.01, t test); error bars represent S.D.
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Pretreatment of G2 Peptide to the Target Cell Significantly
Affects Cell-to-cell Fusion and Viral Spread—Because G2 was
isolated against 3-OS HS, which can mediate viral penetration
by promoting membrane fusion (13), we decided to test
whether G2 also possesses the ability to block the membrane
fusion induced by HSV-1 glycoproteins (32). The same mem-
brane fusion is used during polykaryocytes formation and cell-
to-cell spread (33, 37). 3-OST-3 expressing CHO-K1 cells and
primary cultures of humanCFwere preincubated with G2 pep-
tide followed by co-culturewith effectorCHO-K1 cells express-
ing HSV-1 glycoproteins. The membrane fusion that ensues
upon co-culturing the cells can be estimated by a luciferase-
based reporter assay (32). Likewise, the polykaryocytes forma-
tion can be visualized by Giemsa staining. Evidently, a prior
treatment with G2 was very effective in blocking membrane
fusion (Fig. 7, A and C), and this ability also translated into the
loss of syncytia formation (Fig. 7, Ba and Da) compared with
mock-treated cells (Fig. 7, Bb and Db). These findings indicate
that G2 not only blocks attachment, but it can also inhibit viral
penetration by blocking membrane fusion.
G1 and G2 Peptides Show Protective Effects against HSV-1
Infection of theMouseCornea—Finally, we tested the abilities of
G1 and G2 peptides against HSV-1 infection in amousemodel.
We targeted mouse cornea for two reasons. First, the cornea is
known to express many gD receptors including 3-OS HS (27,
33). Second, cornea is an attractive target for HSV-1 infection
leading to the development of herpetic stromal keratitis, a
potential blinding disease common in developed countries
including the United States (38). Immunohistochemistry was
used to locate HSV-1 gD expression in the cornea pretreated
with either a control peptide, G1, or G2 followed by HSV-1
infection. In sections of cornea ofmice euthanized at the fourth
and seventh days after pretreatment with Cp peptide (control)
followed by virus inoculation demonstrated severe chronic
inflammation combinedwith significant staining for HSV-1 gD
on day 4 (Fig. 8, panel a). HSV-1 staining was gone by day 7,
which is typical with normal mice; however, damage to the
corneal epitheliumwas still evident (Fig. 8, panel b). In contrast,
virtually no HSV-1 protein expression was detected in the cor-
neas treated with G1 or G2 peptide, and the epithelium
remained intact at both 4 and 7 days post-infection (Fig. 8,
panels b, c, e, and f). These findings prove two important points
that anti-HS and anti-3-OS HS peptides show strong promise
as anti-HSV prophylactic agents and that HS is an important
co-receptor for an ocular HSV-1 infection in vivo.
DISCUSSION
In this report we used phage display peptide library screening
as a way to identify small and easily synthesizable peptides that
specifically bind HS and/or 3-OS HS. The two most frequently
isolated peptides, one against commercially found HS (G1) and
the other against specifically modified 3-OS HS (G2), were
investigated for their ability to block HSV-1 entry and spread.
The entry blocking activity of the peptides was not dependent
on any particular gD receptor, virus strain, or cell type used.We
also found that the peptides function by interfering with the
binding ofHSV-1 to cells. To our understanding ours is the first
demonstration of small 12-mer peptides specifically screened
against HS/3-OS HS that block virus attachment and thereby
inhibit viral entry.
Our library screening resulted in isolation of 200 HS bind-
ing phages. The peptides encoded by the phages were
enriched in basic amino acid residues, and they were classi-
fied into two major groups. In The first group, represented
FIGURE 7. Effect of G2 on HSV-1 glycoprotein induced cell-to-cell fusion
and spread. A, the effector CHO-K1 cells expressing HSV-1 glycoproteins
(B, D, H–L, and T7 polymerase) were preincubated with G2 peptide (black bar)
or 1  PBS (white bar) () for 90 min. Control effector cells (T7 polymerase and
glycoproteins gD, H–L only) () were also preincubated with G2 for the same
duration. The effector cells were then mixed with primary cultures of human
corneal fibroblasts (panels A and B) or 3-OST-3-expressing CHO-K1 cells (pan-
els C and D) transfected with luciferase gene under T7 control. Membrane
fusion as a surrogate for viral spread was detected by monitoring luciferase
activity (panels A and C). Relative luciferase units (RLUs) were determined
using a Sirius luminometer (Berthold detection systems). Error bars represent
S.D. *, p  0.05, one way analysis of variance. Microscopic images of Giemsa
(Fluka)-stained polykaryocytes show the preventative effect of G2s on cell
fusion (panels B and D). Shown above are 40 magnified photographs of cells
undergoing membrane fusion (Zeiss Axiovert 200).
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by G1, the sequences had basic amino acids after every resi-
due (XRXRXKXXRXRX). In the second group, represented by
G2, repeats of basic amino acids (XXRRRRXRRRXK) were
observed. This is very interesting because G2 was isolated
against 3-OS HS, and alanine-scanning mutagenesis suggested
that the repeats, especially the first one, were essential for entry
inhibition (Fig. 4B). Unlike G1, G2 also blocks the entry of two
divergent herpesviruses, CMV and HHV-8 (7). In addition, we
also found that G2 blocks membrane fusion as well, which
means the peptide can interfere with gD interaction with its
receptor, 3-OS HS (39–41). Among the structural differences
betweenG1 andG2, it appears thatG2 showsmore dependence
on the positively charged residues than G1, which is probably
also dependent on the presence of a Lys residue at the N termi-
nus. In general, arginine has been found important for charge-
charge interaction with HS (42).
The ability of our peptides to act specifically on HS/3-OSHS
is highly significant for many additional reasons. First, HS is
widely expressed on all cells and tissues, and it is known to
regulate many important biological phenomena (16, 43). Our
peptides can be used as probes to study HS functions. Second,
many times HS moieties are up-regulated especially during
pathological conditions, and they themselves may also contrib-
ute to inflammation (16). Our peptidesmay find usage in block-
ing pathological effects of HS and regulating inflammation as
well. Third, a complex enzymatic regulation of HS chain gives
HS an equally complex ability (and affinity) to bind many pro-
teins to perform new functions (16, 43). The 3-OS HS binding
peptide may be used as a probe or a diagnostic tool to assess
structural alterations within HS or its turnover on cell surfaces.
Overall, the peptides cannot only be used against viral infec-
tions but also for many additional unrelated applications. Even
for anti-viral activity,many unrelated viruses bindHS (4), and it
is quite possible that G2 may have the ability to block infection
of many additional viruses, a possibility that requires further
scrutiny.
One additional and a very important use of the peptides is to
demonstrate the significance of HS during an actual HSV-1
infection in vivo. Although HS has been well studied as an
attachment receptor (7), very limited information is available
on its usage in vivo. Our experiments using a mouse corneal
infection model not only show the efficacy of the peptides in
blocking infection in vivo, but it also shows thatHS is an impor-
tant HSV-1 coreceptor, not only for cultured cells but also for
the cells in vivo (Fig. 8). Mice treated with either G1 or G2 did
not show any obvious symptoms of infection, and likewise, a
key viral protein was undetectable. Future experiments will
determine whether a prior treatment with G1 and G2 can also
stop the virus from establishing a latent infection or not. Like-
wise, it will be interesting to see the effects G1 andG2may have
on an existing HSV-1 infection (therapeutic potential) and
effects of G2 on other viral infections. It will also be very impor-
tant to determine the fate of the peptide(s) once it is bound to
the cell surface HS.We have been unable to detect any redistri-
bution of HS on cell surfaces; however, it is quite possible that
the peptide is internalized, and itmay eventually be delivered to
the nucleus.3 In that case the peptide(s) may provide an inter-
esting vehicle for gene and protein delivery to the nucleus. In
any case, interfering with virus entry is an attractive prophylac-
tic strategy that may have the ability to control virus infection
and prevent transmission. We have provided the proof of prin-
ciple for a possible clinical benefit of our peptides.
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